Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia

HDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circu...

Full description

Bibliographic Details
Main Authors: Thomas M. van Himbergen, Mark Roest, Jacqueline de Graaf, Eugène H.J.M. Jansen, Hiroaki Hattori, John J.P. Kastelein, Hieronymus A.M. Voorbij, Anton F.H. Stalenhoef, Lambertus J.H. van Tits
Format: Article
Language:English
Published: Elsevier 2005-03-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520340281
id doaj-196cd4817bef461aa3c81373da2dc325
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Thomas M. van Himbergen
Mark Roest
Jacqueline de Graaf
Eugène H.J.M. Jansen
Hiroaki Hattori
John J.P. Kastelein
Hieronymus A.M. Voorbij
Anton F.H. Stalenhoef
Lambertus J.H. van Tits
spellingShingle Thomas M. van Himbergen
Mark Roest
Jacqueline de Graaf
Eugène H.J.M. Jansen
Hiroaki Hattori
John J.P. Kastelein
Hieronymus A.M. Voorbij
Anton F.H. Stalenhoef
Lambertus J.H. van Tits
Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
Journal of Lipid Research
atherosclerosis
antioxidants
polymorphisms
author_facet Thomas M. van Himbergen
Mark Roest
Jacqueline de Graaf
Eugène H.J.M. Jansen
Hiroaki Hattori
John J.P. Kastelein
Hieronymus A.M. Voorbij
Anton F.H. Stalenhoef
Lambertus J.H. van Tits
author_sort Thomas M. van Himbergen
title Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
title_short Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
title_full Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
title_fullStr Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
title_full_unstemmed Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
title_sort indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2005-03-01
description HDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circulating oxidized LDL (OxLDL), subclinical inflammation [high-sensitive C-reactive protein (Hs-CRP)], and carotid atherosclerosis. PON1 genotypes (L55M, Q192R, −107C/T, −162A/G, −824G/A, and −907G/C) were determined in 302 patients with familial hypercholesterolemia. PON1 activity was monitored by the hydrolysis rate of paraoxon, diazoxon, and phenyl acetate. PON1 levels, OxLDL, and Hs-CRP were determined using an immunoassay. The genetic variants of PON1 that were associated with high levels and activity of the enzyme were associated with higher HDL-C levels (P values for trend: 0.008, 0.020, 0.042, and 0.037 for L55M, Q192R, −107C/T, and −907G/C, respectively). In addition to the PON1 genotype, there was also a positive correlation between PON1 levels and activity and HDL-C (PON1 levels: r = 0.37, P < 0.001; paraoxonase activity: r = 0.23, P = 0.01; diazoxonase activity: r = 0.29, P < 0.001; arylesterase activity: r = 0.19, P = 0.03).Our observations support the hypothesis that both PON1 levels and activity preserve HDL-C in plasma.
topic atherosclerosis
antioxidants
polymorphisms
url http://www.sciencedirect.com/science/article/pii/S0022227520340281
work_keys_str_mv AT thomasmvanhimbergen indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT markroest indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT jacquelinedegraaf indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT eugenehjmjansen indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT hiroakihattori indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT johnjpkastelein indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT hieronymusamvoorbij indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT antonfhstalenhoef indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
AT lambertusjhvantits indicationsthatparaoxonase1contributestoplasmahighdensitylipoproteinlevelsinfamilialhypercholesterolemia
_version_ 1721506425457344512
spelling doaj-196cd4817bef461aa3c81373da2dc3252021-04-27T04:46:26ZengElsevierJournal of Lipid Research0022-22752005-03-01463445451Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemiaThomas M. van Himbergen0Mark Roest1Jacqueline de Graaf2Eugène H.J.M. Jansen3Hiroaki Hattori4John J.P. Kastelein5Hieronymus A.M. Voorbij6Anton F.H. Stalenhoef7Lambertus J.H. van Tits8Research Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsResearch Laboratory of the Department of Clinical Chemistry, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Medicine, Division of General Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; Laboratory for Toxicology, Pathology, and Genetics, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Department of Advanced Medical Technology and Development, BML, Inc., Saitama 350-1101, Japan; Department of Vascular Medicine, Academic Medical Center, Amsterdam, The NetherlandsHDL-associated paraoxonase type 1 (PON1) can protect LDL and HDL against oxidative modification in vitro and therefore may protect against cardiovascular disease. We investigated the effects of PON1 levels, activity, and genetic variation on high density lipoprotein-cholesterol (HDL-C) levels, circulating oxidized LDL (OxLDL), subclinical inflammation [high-sensitive C-reactive protein (Hs-CRP)], and carotid atherosclerosis. PON1 genotypes (L55M, Q192R, −107C/T, −162A/G, −824G/A, and −907G/C) were determined in 302 patients with familial hypercholesterolemia. PON1 activity was monitored by the hydrolysis rate of paraoxon, diazoxon, and phenyl acetate. PON1 levels, OxLDL, and Hs-CRP were determined using an immunoassay. The genetic variants of PON1 that were associated with high levels and activity of the enzyme were associated with higher HDL-C levels (P values for trend: 0.008, 0.020, 0.042, and 0.037 for L55M, Q192R, −107C/T, and −907G/C, respectively). In addition to the PON1 genotype, there was also a positive correlation between PON1 levels and activity and HDL-C (PON1 levels: r = 0.37, P < 0.001; paraoxonase activity: r = 0.23, P = 0.01; diazoxonase activity: r = 0.29, P < 0.001; arylesterase activity: r = 0.19, P = 0.03).Our observations support the hypothesis that both PON1 levels and activity preserve HDL-C in plasma.http://www.sciencedirect.com/science/article/pii/S0022227520340281atherosclerosisantioxidantspolymorphisms